Moelis shares slide while analysts debate M&A recovery

Moelis & Company heads into this week with a curious split: the stock fell nearly 9% on the week to $63.49, while short sellers were actually trimming rather than pressing. That divergence — selling pressure without a corresponding build in short conviction — frames the key question around this name right now.

The short-side story is measured, not extreme. Short interest runs at 7.5% of the free float, up about 8% over the past month as a whole, but the trend reversed sharply this week — down nearly 3% over five days. Borrow costs have stayed consistently cheap, holding around 0.40% APR with little volatility. The lending pool remains well-supplied, and the ORTEX short score has drifted lower from a recent high of 53.3 on April 24 to just over 51 today — suggesting short-side conviction has eased, not built, as the stock weakened. Availability, though not at extremes, has remained relatively comfortable throughout. This is not a crowded short.

Options positioning tells a subtly different story. Put/call interest has risen to 0.32, running well above the 20-day average of 0.19 and roughly 1.5 standard deviations elevated. That is still modest relative to the 52-week range — the top was 1.24 and the floor 0.07 — but the direction of travel since late April is clear: investors have added more put protection as the stock has pulled back. The shift is defensive, not aggressive.

The Street is broadly cautious, with no analyst holding a Buy after a wave of target cuts in early April. Morgan Stanley kept its Overweight but lowered its target to $83 from $90. Goldman Sachs and UBS both reiterated Neutral, with Goldman cutting to $62 from $70 and UBS moving to $58. Keefe, Bruyette & Woods brought its Market Perform target down from $80 to $64 in one of the sharper reductions. The consensus mean now sits at $70, implying about 10% upside from the current price — thin enough that valuation support is marginal for most holders. The P/E multiple has expanded about 3 points over the past month to roughly 18.8x, reflecting mostly the earnings base rather than a re-rating higher; the price-to-book, at 8.6x, has climbed nearly 1.4 points in 30 days, a function of the stock's prior month gain of 12.8%. On factor scores, EPS momentum is weak — just the 8th percentile on 30-day momentum — while the dividend score ranks in the 89th percentile, consistent with the company's history of returning capital to shareholders.

Moelis posted a 6.6% one-day drop after its April 29 earnings release, the only clean data point in the history window. The bull case rests on what management called "record new business origination" and a "record pipeline," with revenues of $307 million topping estimates by around 3%. The bear case centres on a modest shortfall in adjusted EPS and a dip in the sponsor backlog, with management flagging some deal deferrals — a concern that weighs more heavily when the broader M&A backdrop remains uncertain.

Peer performance this week underscores that this is an industry-wide story, not a Moelis-specific one. Evercore fell 4.2% and Lazard was down 7% on the week; Piper Sandler dropped 8.5%. Only Jefferies bucked the trend, rising nearly 4%. The next scheduled earnings event is July 29 — the gap before then means the M&A volume read will come through deal announcements and sector news rather than any Moelis-specific catalyst. The pace of sponsor-backed transactions returning to market after the spring deferral wave is what the tape will be watching.